With IPOs not an option, should pharma feed the biotech ecosystem?

This year's J.P. Morgan Healthcare Conference had its share of bright new ideas and pioneering technologies, tempered by the simple reality that key financial trends on tap for 2012 have already been playing out for several tough years. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.